G1 Therapeutics and Simcere Announce Exclusive License Agreement for Trilaciclib in Greater China
Simcere to lead clinical development, regulatory submissions and commercialization of trilaciclib across all indications in Greater China G1 to receive $14 million upfront payment, sales royalties and up to $156 million in future milestone payments …